Reporter brief
ALSENLITE: An Open-Label Pilot Study of Senolytics for Alzheimer's Disease
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy data are reported; this pilot describes only safety and feasibility objectives.
- Open-label design without control group cannot establish that any observed changes result from treatment rather than natural progression or placebo effect.
- Sample size is not reported, limiting the ability to assess how many participants were evaluated.
Study design and sample
Other; Human.
Subjects with Mild Cognitive Impairment (MCI) or Alzheimer's disease
- Design
- Other
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Jul 17, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.